Research Disclaimer: All compounds described are sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.
Growth hormone (GH) axis research in Europe encompasses a range of compound types: recombinant human GH (somatropin), GHRH analogs (CJC-1295), GHSR-1a agonists (ipamorelin, GHRP-2, GHRP-6), and oral GH secretagogues (MK-677). Each has different synthesis complexity, quality requirements, and research applications. This guide helps European researchers select the right compound and verify they're sourcing research-grade material.
GH Research Compound Categories#
Recombinant HGH (Somatropin):
- 191-amino acid protein identical to endogenous human GH
- Produced by recombinant DNA technology (E. coli or mammalian expression)
- Available as lyophilized vials (4 IU, 10 IU, 36 IU)
- Requires refrigeration; reconstitute with BAC water
- Quality markers: SDS-PAGE identity, HPLC purity, biological potency assay (IGF-1 stimulation)
GHRH Analogs:
- CJC-1295 (without DAC): 2mg vials; mimics GHRH; t½ ~30 min; requires twice-daily dosing in research
- CJC-1295 with DAC: 2mg/5mg vials; DAC modification (Drug Affinity Complex) extends t½ → once weekly dosing
- MOD GRF 1-29: modified GHRH fragment; common GHRH research tool
GHSR-1a Agonists (ghrelin mimetics):
- Ipamorelin: 5mg/10mg vials; most selective (minimal cortisol/prolactin off-target)
- GHRP-2: 5mg vials; more potent GH release; some prolactin elevation
- GHRP-6: 5mg vials; appetite stimulation + GH; GHSR-1a + ghrelin axis research
- Hexarelin: 5mg vials; most potent GHRP; cardiac receptor activity (non-GHSR mechanism)
Oral GH Secretagogue:
- MK-677 (Ibutamoren): oral GHSR-1a agonist; 10mg/25mg capsules or tablets; long t½ (~24h)
Quality Requirements by Compound Type#
Peptide GH secretagogues (ipamorelin, CJC-1295, GHRP-2):
- HPLC purity ≥98%
- ESI-MS identity confirmation
- Endotoxin ≤1 EU/mg
- Janoshik or equivalent independent lab COA
- Batch-specific documentation
MK-677:
- Small molecule (MW 624 Da), not a peptide
- HPLC purity ≥99% (high-purity standard for small molecules)
- MS confirmation: [M+H]+ at m/z 625.1
- Endotoxin testing applies if used in solution for in vivo work
Recombinant HGH:
- Bioactivity assay (Nb2 cell or IGF-1 stimulation): confirms functional GH activity
- SDS-PAGE: single band at ~22 kDa (monomeric GH)
- SEC-HPLC: ≥95% monomer (aggregates impair bioactivity)
Research Applications by Compound#
| Compound | Primary research application | Dosing frequency in studies |
|---|---|---|
| Ipamorelin | Pulsatile GH release; selective GH secretagogue | Twice daily (q12h) |
| CJC-1295 DAC | Sustained GH/IGF-1 elevation; somatopause models | Once weekly |
| GHRP-2 | GH pulse amplitude; compare to ipamorelin | Twice to three times daily |
| MK-677 | Chronic IGF-1 elevation; oral bioavailability | Once daily |
| HGH Fragment 176-191 | Selective lipolysis without IGF-1 | Twice daily |
| Recombinant HGH | Full GH axis replacement; anabolic + metabolic | Daily or every other day |
EU Stock Advantages for GH Peptides#
GH secretagogue peptides are temperature-sensitive and benefit greatly from EU-based supply:
- Short transit times (2–5 days EU-to-EU) → minimal thermal stress
- No customs delays or inspection → predictable delivery for research continuity
- EU-lab COA verification → traceable quality documentation
Research Use Only. JuicedPharma does not provide medical advice.
Published by JuicedPharma Research Team · October 2026 · Category: Growth Hormone
